Transitioning Your Product from Phase I to Phase II Clinical Studies ‒ How a CDMO Can Help

By Upperton Pharma Solutions

Completing a Phase I clinical study is a major milestone for your development programme and there are multiple considerations for the team depending on the drug product used in the study and the clinical outcome.

A partnership with a CDMO can help to define and implement the best pathways. This free white paper explores the key considerations you need to take to ensure a successful transition, focusing on solid oral dosage forms (tablets and capsules).

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sections

Sections

Sections

Sections

Sections